Inactive Instrument
ReNeuron Group plc Stock
Stocks
RENE
GB00BF5G6K95
Biotechnology & Medical Research
OTC Markets Traded
| 06/02/24 | RENEURON ISSUES ADMINISTRATION WARNING | AQ |
| 27/11/23 | Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™ | EQ |
| 16/11/23 | ReNeuron : Interim Statement 2023 | PU |
| 08/11/23 | ReNeuron : Presentation | PU |
| 24/07/23 | ReNeuron : 24 July 2023 – Notice of Annual General Meeting | PU |
| 1 day | -2.17% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 24/03/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Iain Ross
CHM | Chairman | 72 | 01/07/2021 |
| Director/Board Member | 63 | 14/07/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/07/23 | Buy | Chief Financial Officer | 52,332 | 0.0915% | ||
| 16/06/23 | Buy | Director | 150,000 | 0.2624% | ||
| 16/06/23 | Buy | Chairman | 150,000 | 0.2624% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.17% | -11.18% | - | - | 2.58M | |
| -3.10% | -4.19% | +32.67% | +59.47% | 63.48B | |
| +0.59% | +0.10% | +10.53% | +80.02% | 54.55B | |
| -1.42% | +0.58% | +10.00% | +101.35% | 53.59B | |
| -0.75% | +1.38% | +24.89% | +50.91% | 44.75B | |
| -1.30% | -4.80% | +16.05% | +114.76% | 41.62B | |
| +1.26% | -5.26% | +221.12% | +900.64% | 39.91B | |
| -0.74% | -4.46% | +11.00% | +44.65% | 32.47B | |
| +0.27% | +14.47% | +60.59% | +50.63% | 26.7B | |
| +3.72% | -6.23% | +26.01% | -8.28% | 23.36B | |
| Average | -0.37% | -1.19% | +45.87% | +154.91% | 42.27B | |
| Weighted average by Cap. | -0.55% | -1.27% | +43.04% | +155.56% |
Employees
26
